GLOW

What it is

GLOW is not a single peptide. It is a pre-mixed blend of three: GHK-Cu (the copper peptide, known for skin and hair), BPC-157 (associated with tissue and gut healing) and TB-500 (a thymosin beta-4 fragment associated with repair and recovery). The name is a marketing label used by research-peptide sellers.

The most common version is a 70 mg vial made of 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500. The appeal is convenience: one vial and one injection instead of three. The catch is that nobody has studied this combination in people, so the evidence is whatever exists for each ingredient separately.

History

The blend has no research history of its own. It appeared in the research-peptide market in the mid-2020s as a "cosmetic and recovery" stack. The ingredients are older: GHK-Cu was identified in the early 1970s, BPC-157 in the early 1990s, and TB-500 is derived from thymosin beta-4, which has been studied since the 1980s.

How it works

There is no mechanism data for the combination, only for the parts. GHK-Cu delivers copper and influences collagen production and gene expression linked to wound healing. BPC-157 is thought to promote new blood vessel growth and tissue repair signalling. TB-500 is thought to affect actin, a protein involved in cell movement, which may help cells migrate to injury sites. Whether they add up, overlap or do nothing together has not been tested.

Dosage

• There is no standard dose. Sellers and communities usually dose by the BPC-157 and TB-500 content, because those are the lower-dose components.
• A commonly reported range is about 0.25–0.5 mg of BPC-157 and TB-500 per injection, which delivers roughly 1.25–2.5 mg of GHK-Cu alongside it, once daily or a few times a week.
• Typical courses reported are 4–8 weeks, then a break. These figures are extrapolated from the individual peptides and community reports, not from trials.
• Because the ratio is fixed (about 5:1:1), you cannot adjust one component without changing the others. If you want a different dose of any one of them, separate vials are the only way.

How it is taken

• Subcutaneous injection into belly fat with a 29–31G insulin syringe is the usual route.
• Some users inject near the area they care about, such as the face or scalp for skin and hair goals, or close to an injury. The evidence that this works better than injecting elsewhere is weak.
• Rotate injection sites to reduce irritation and lumps.

How to reconstitute

• For the common 70 mg vial (50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500), add 2 ml of bacteriostatic water. That gives 35 mg/ml of total blend.
• At that concentration, 5 units on a 1 ml insulin syringe (0.05 ml) is about 1.75 mg of blend: roughly 1.25 mg GHK-Cu, 0.25 mg BPC-157 and 0.25 mg TB-500. 10 units doubles each of those.
• Check the label first. Some sellers use different ratios or vial sizes, and the arithmetic changes with them. Always work from the amounts on your own vial.
• Add the water slowly down the inside wall of the vial. Swirl gently to dissolve. Do not shake.

How it should arrive

Sealed glass vial with an intact crimped cap and a powder cake at the bottom. Because GHK-Cu is blue-green, the powder should look pale blue to teal, not pure white. A fully white powder in a GLOW vial suggests the GHK-Cu is missing or heavily under-dosed.

How it should look once reconstituted

A clear blue or blue-green solution with no cloudiness, flecks or residue. A colourless solution is a red flag. A very pale tint can be normal at low GHK-Cu amounts, but a vial labelled 50 mg GHK-Cu should be obviously coloured.

What to expect, and when

• Wound or injury recovery: anecdotally 2–6 weeks, based on the BPC-157 and TB-500 components.
• Skin texture and tone: 4–8 weeks at the earliest, based on GHK-Cu evidence.
• Hair changes: GHK-Cu hair studies run 3–6 months, so do not expect anything faster.
• If you notice nothing after 6–8 weeks of consistent use, the realistic conclusion is that it is not doing anything for you.

Side effects

• Most reports describe it as well tolerated.
• Injection-site redness, itching, stinging or small lumps. GHK-Cu can cause temporary blue-ish discolouration at the site.
• Occasional headache, tiredness or flushing, reported for the BPC-157 and TB-500 components.
• With a blend, you cannot tell which ingredient caused a reaction without stopping and testing them separately.

Risks

• No human safety data exists for the combination. The safety picture is borrowed from the individual peptides, and BPC-157 and TB-500 themselves have almost no controlled human data.
• BPC-157 and TB-500 are both thought to promote blood vessel growth and tissue repair. That is why they are interesting, and also why long-term safety, including tumour risk, has not been ruled out. If you have a cancer history or a suspected tumour, this is a good reason to avoid them.
• Quality varies a lot. Blends are harder to verify than single peptides: a seller can under-dose or leave out a component and the vial can still look plausible. Independent third-party testing of the blend is the only real check.
• You may be paying for 50 mg of GHK-Cu you do not need. GHK-Cu is cheap on its own and has decent topical evidence, so a blend can be poor value.
• BPC-157 and TB-500 are both banned for competitive athletes under WADA rules.

Potential gains

• Convenience: one vial and one injection in place of three.
• Skin firmness and tone, and possibly hair density, from the GHK-Cu component. This is the best-evidenced part, mostly from topical use.
• Soft-tissue and wound recovery, based on animal studies and anecdote for BPC-157 and TB-500.
• No trial shows the combination works better than the individual peptides.

Other useful information

If your main goal is skin or hair, topical GHK-Cu has the strongest evidence and the lowest risk, and you do not need a blend for it. If your goal is a specific injury, BPC-157 and TB-500 on their own let you control the dose of each. GLOW makes most sense if you already want all three and accept the fixed ratio. Related blends exist, such as ones that add KPV, so always read the label rather than going by the name.